Bioglutide (NA-931)

Human clinical Weight Loss & Metabolism 2 sources

Bioglutide (NA-931) is an investigational oral small-molecule quadruple receptor agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors. Currently in Phase 2 clinical trials, it is designed to promote significant weight loss while preserving muscle mass and minimizing common gastrointestinal side effects associated with traditional therapies.

01Dosing reference

Amount

Investigational (Clinical trial dosing not fully public)

Frequency

Once daily

Cycle

Continuous daily use

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Quadruple Receptor Activation

Bioglutide binds to and activates GLP-1, GIP, glucagon (GCGR), and IGF-1 receptors simultaneously.

Metabolic and Anabolic Synergy

GLP-1 and GIP enhance insulin secretion and satiety, glucagon increases energy expenditure, and IGF-1 promotes muscle protein synthesis.

Fat Loss with Muscle Preservation

This combined action leads to significant reductions in adipose tissue while preventing the lean muscle mass loss typically seen with rapid weight loss.

03Human evidence

Phase 2 clinical trials indicate significant reductions in body weight and fat mass in obese subjects.

Ongoing Phase 2B trials by Biomed Industries evaluating oral administration for obesity and type 2 diabetes.

Early data suggests improved tolerability and preservation of lean muscle mass compared to traditional GLP-1 agonists.

Clinical evaluations focusing on mitigating gastrointestinal side effects and muscle wasting.

04Preclinical evidence

Demonstrated synergistic effects on weight reduction and glycemic control in animal models of obesity.

Rodent models evaluating the quadruple agonist approach versus single or dual agonists.

Showed protective effects on lean body mass during caloric deficit.

Preclinical assessments of the IGF-1 receptor activation component.

05What is known vs. unknown

Reasonably established

It is an oral small molecule, not an injectable peptide, making it more convenient for patients.
Targets four distinct metabolic pathways: GLP-1, GIP, Glucagon, and IGF-1.
The inclusion of IGF-1 receptor activation is specifically aimed at preserving muscle mass during weight loss.
Currently in Phase 2 clinical trials for obesity and Type 2 Diabetes.

Unknowns & limits

Long-term safety and efficacy data in large human populations are not yet available.
The exact degree of muscle preservation compared to diet and exercise alone remains to be fully quantified in Phase 3 trials.
Potential off-target effects of systemic IGF-1 activation require careful long-term monitoring.

06Safety & regulatory context

Regulatory statusBioglutide (NA-931) is currently an investigational drug in Phase 2 clinical trials and is not FDA-approved for any indication. While early data suggests it may have a more favorable gastrointestinal side effect profile than traditional GLP-1 agonists, comprehensive safety data is still being gathered. Potential risks could relate to its multi-receptor activation, particularly systemic IGF-1 stimulation, which requires monitoring for cellular proliferation risks. It should only be used in approved clinical trial settings.

07Compared with Retatrutide

Bioglutide (NA-931) vs. Retatrutide

Key difference

While Retatrutide is an injectable triple agonist (GLP-1, GIP, Glucagon), Bioglutide is an oral quadruple agonist that adds IGF-1 receptor activation to specifically preserve muscle mass.

When researchers discuss each

Researchers discuss Retatrutide for maximum weight loss efficacy via triple agonism, whereas Bioglutide is highlighted for its oral bioavailability and unique muscle-sparing potential during weight loss.

08Glossary

Quadruple Agonist

A compound that activates four different cellular receptors simultaneously to produce a combined effect.

IGF-1 (Insulin-like Growth Factor 1)

A hormone that plays a key role in childhood growth and continues to have anabolic effects in adults, helping to build and preserve muscle.

Small Molecule

A low molecular weight compound that can easily enter cells and is often suitable for oral administration, unlike larger peptides or proteins.

09Knowledge check

Q1Which unique receptor does Bioglutide target to help preserve muscle mass during weight loss?

Q2How is Bioglutide administered?

Q3Which documented limitation about Bioglutide is explicitly stated in the dossier's 'unknownsAndLimits' section?

Q4According to the dossier, what is the key contextual difference researchers use when comparing Bioglutide with Retatrutide?

Q5Which statement about Bioglutide's regulatory and safety status is supported by the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.